Eli Lilly and Company announced that the primary study objective from three studies of edivoxetine for superior efficacy was not met in depression after eight weeks of treatment. Edivoxetine  is a highly selective norepinephrine reuptake inhibitor (SSRI) being studied as adjunctive treatment in patients with major depressive disorder (MDD).

RELATED: Psychiatric Disorders Resource Center

In 2010, Lilly launched the Phase 3 program for edivoxetine to focus on meeting the unmet needs of patients with major depression who had achieved only a partial response to treatment with an SSRI.  In these three trials, patients remained on SSRI treatment and additionally received either edivoxetine or placebo.  When added to a SSRI, edivoxetine did not separate from placebo on the Montgomery-Asberg Depression Rating Scale (MADRS) in the three acute randomized placebo-controlled Phase 3 studies (LNBM, LNBQ and LNBR).

The efficacy results did not support regulatory submission as adjunctive treatment in patients with major depressive disorder.

For more information call (800) 545-5979 or visit Lilly.com.